Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial

NCT04562532 is registered in ClinicalTrials.gov with Shanghai MicroPort Medical (Group) Co., Ltd. as lead sponsor.

NCT NCT04562532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 17, 2021
Completion date
June 30, 2027
Enrollment
1,720 (estimated)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease